These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 3472420)

  • 1. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
    Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
    Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
    Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
    Nouts A; Lévy P; Voitot H; Bernades P
    Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
    Charneau J; Douay O; Daver A; Boyer J
    Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products.
    Kalthoff H; Kreiker C; Schmiegel WH; Greten H; Thiele HG
    Cancer Res; 1986 Jul; 46(7):3605-7. PubMed ID: 3708591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor markers of pancreatic cancer].
    Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
    Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
    Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
    Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M; Metzger U; Joller H; Largiadèr F
    Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.